Revolution Medicines, Inc. (RVMD)
After hours:
| Previous close | 49.50 |
| Open | 49.43 |
| Bid | 36.00 x 200 |
| Ask | 50.60 x 200 |
| Day's range | 49.19 - 50.83 |
| 52-week range | 15.44 - 51.00 |
| Volume | |
| Avg. volume | 1,193,200 |
| Market cap | 8.432B |
| Beta (5Y monthly) | 1.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.72 |
| Earnings date | 04 Nov 2024 - 08 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 60.08 |
GlobeNewswireRevolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentationsREDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced seven oral and poster presentations will be featured at the 2024 AAC
Insider MonkeyRevolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks
We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to take a look at where Revolution Medicines, Inc. (NASDAQ:RVMD) stands against the other biotech stocks. The ability to successfully make money through investment requires deep thinking and analysis. Even then, it’s not […]
Simply Wall St.Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)
Revolution Medicines ( NASDAQ:RVMD ) First Half 2024 Results Key Financial Results Net loss: US$249.2m (loss widened by...
